Literature DB >> 20001853

Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.

Pamela A Moise1, Alan Forrest, Arnold S Bayer, Yan Q Xiong, Michael R Yeaman, George Sakoulas.   

Abstract

BACKGROUND: Vancomycin susceptibility, the accessory gene global regulator (agr) genotype and function, staphylococcal cassette chromosome (SCC) mec type, and susceptibility to cationic thrombin-induced platelet microbicidal protein 1 (tPMP-1) have been individually predictive of duration of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. This investigation evaluated the interrelationship of these factors with time to clearance of MRSA bacteremia during vancomycin therapy in patients without endocarditis.
METHODS: Vancomycin minimum inhibitory concentration and in vitro killing, agr function (delta-hemolysin activity), agr group, SCCmec type, and survival in tPMP-1 killing assays were determined for 29 MRSA bacteremia isolates.
RESULTS: Increased resistance to tPMP-1 killing was observed with agr group III MRSA (P = .025) and MRSA with reduced or absent agr function (P = .023). The median time to clearance of MRSA bacteremia was earlier for agr group III (3 days) versus group I (10.5 days) or II (15 days) (P = .001). In multivariate analysis, agr group II, reduced tPMP-1 killing in vitro, and prior vancomycin exposure were significant independent predictors of longer MRSA bacteremia duration.
CONCLUSIONS: Specific genotypic, phenotypic, and clinical parameters appear to correlate with persistent MRSA bacteremia. The interrelationship of these and other factors probably contributes to vancomycin-mediated clearance of MRSA bacteremia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001853      PMCID: PMC2819315          DOI: 10.1086/649429

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Carlo McCalla; Davida S Smyth; D Ashley Robinson; Judith Steenbergen; Steven A Luperchio; Pamela A Moise; Vance G Fowler; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

5.  Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  T P Lodise; C D Miller; J Graves; A Evans; E Graffunder; M Helmecke; K Stellrecht
Journal:  J Antimicrob Chemother       Date:  2008-08-11       Impact factor: 5.790

6.  Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

7.  Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer
Journal:  Int J Antimicrob Agents       Date:  2008-08-12       Impact factor: 5.283

8.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

9.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

10.  Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Pamela A Moise; Davida S Smyth; Nadia El-Fawal; D Ashley Robinson; Patricia N Holden; Alan Forrest; George Sakoulas
Journal:  J Antimicrob Chemother       Date:  2007-11-27       Impact factor: 5.790

View more
  15 in total

1.  Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.

Authors:  Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.

Authors:  Wessam Abdelhady; Liang Chen; Arnold S Bayer; Kati Seidl; Michael R Yeaman; Barry N Kreiswirth; Yan Q Xiong
Journal:  J Antimicrob Chemother       Date:  2015-01-05       Impact factor: 5.790

3.  The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus.

Authors:  Wei Gao; David R Cameron; John K Davies; Xenia Kostoulias; Justin Stepnell; Kellie L Tuck; Michael R Yeaman; Anton Y Peleg; Timothy P Stinear; Benjamin P Howden
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

4.  Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus In Vitro.

Authors:  Sarah E Hobdey; Eva J Katahira; Pamela Dockstader; Stephen M Davidson; Laura Bond; Devin D Bolz; Amy E Bryant; Dennis L Stevens
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Kati Seidl; Liang Chen; Arnold S Bayer; Wessam Abdel Hady; Barry N Kreiswirth; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

6.  Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.

Authors:  Warren E Rose; Michael Fallon; John J M Moran; Joshua P Vanderloo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients.

Authors:  Nagendra N Mishra; Arnold S Bayer; Pamela A Moise; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2012-08-16       Impact factor: 5.226

9.  Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Authors:  Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.

Authors:  Arnold S Bayer; Nagendra N Mishra; George Sakoulas; Poochit Nonejuie; Cynthia C Nast; Joseph Pogliano; Kuan-Tsen Chen; Steven N Ellison; Michael R Yeaman; Soo-Jin Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.